Sam­sung Bi­o­log­ics nets $330M+ deal from As­traZeneca ahead of 'Su­per Plan­t' con­struc­tion

Just a few weeks af­ter an­nounc­ing plans to con­struct a $2 bil­lion “Su­per Plant,” Sam­sung Bi­o­log­ics is keep­ing its foot on the gas.

The Ko­re­an CD­MO has inked a $330.8 mil­lion man­u­fac­tur­ing con­tract with As­traZeneca, the com­pa­nies an­nounced Mon­day evening, pro­vid­ing the British drug­mak­er the abil­i­ty to ex­pand pro­duc­tion ca­pa­bil­i­ties in the Asia mar­ket. Per terms of the deal, the part­ner­ship could be in­creased to $545.6 mil­lion.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER